~1 hour
Decision turnaround, down from 2 days
Assess360
Find the hereditary-risk patients already in your panel. Assess360 checks every chart against the criteria, with a versioned, tested rules engine deciding and AI only explaining.
You Know Who You Tested. Who Did You Miss?
The guideline, the reimbursement, and the accreditation requirement all exist. What is missing is a system that checks every chart against the criteria, every time, not only the ones a clinic happens to refer. So most who qualify are never identified.
Aligned with every priority in the room.
Cancer Program Director
Today
Your accreditation requires a hereditary-risk process and a running count of who needed a genetic referral and who received one, and today you can't produce it.
With Assess360
Stand up that process with panel-wide screening, and produce the numbers year after year.
Today
Your accreditation requires a hereditary-risk process and a running count of who needed a genetic referral and who received one, and today you can't produce it.
With Assess360
Stand up that process with panel-wide screening, and produce the numbers year after year.
From Patient Panel to Genetic Answer
Screen the Whole Panel
Panel-wide screening checks every chart against the criteria and returns a criteria-matched shortlist, in the time it took to review one chart.
Build the Pedigree, Route the Patient
A three-generation family history assembles automatically for the counselor, and qualifying patients route onward, with cascade family testing built in.
Assess to the Guideline
NCCN-based criteria and a published risk model turn each chart into a structured risk picture.
Explain Every Result in Plain Language
Each determination arrives with a clinician summary and a patient-friendly explanation, ready to use.
What Sets Assess360 Apart
Rules Decide, AI Explains
Every risk level, matched criterion, and billing code is computed by a versioned, tested rules engine. AI only writes the explanation, never the result.
Show Your Work
Every number traces to the criterion and the exact data point behind it, and re-derives to the same answer months later.
Yours to Own, Not Rented from a Lab
White-labelled, configurable, deployed on-premises so PHI never leaves your walls, and lab-neutral, so it is not tied to one testing vendor.
Runs with No AI Service at All
Every determination still computes with no AI provider reachable, so the clinical results never depend on a model being up.
Impact Story
78%
Fewer appeals, from 45 to 10 per 100 cases
6.4 min
Median time from inbound file to created case, down from 3 hours
We took utilization review from days to hours, with a clinician deciding every case.
Faxed requests, long PDFs and manual criteria checks slowed every review and fed a high appeal rate. We built an AI-native utilization management platform that structures intake, summarizes the record and recommends actions, and clinicians make every decision.
Read Case Study
Whitepaper
The Patients You're Not Screening
Most cancer programs can tell you how many patients they tested for a hereditary syndrome last year. Almost none can tell you how many should have been tested and never made it that far. This guide pulls together the independent research on the size of that gap, why clear criteria still miss patients, and what actually closes it.
Frequently Asked Questions
Let’s Talk!
Bhupesh Nadkarni
Head, Healthcare
We build it. You own it.
Our Offices
New York
Dubai
India
